Vector Science develops therapeutic platforms that deliver exactly the right intervention, at exactly the right anatomical site, for exactly the right duration—without systemic exposure. Our organizing framework reflects a principled commitment to precision from first principles.
Every platform Vector Science brings to clinic is organized around three interconnected principles. This is not a marketing construct—it is the engineering logic that runs from formulation through delivery through duration, ensuring that each element of the platform is purpose-built rather than adapted from convention.
Platforms that incorporate data-informed formulation and adaptive delivery logic. Therapeutic compounds are paired with delivery mechanisms that respond to tissue conditions, physiology, and clinical protocol—not a one-size approach. Intelligence begins at the molecular level and extends into how the device communicates with the clinical workflow.
Active, site-directed delivery that guides therapeutic compounds through tissue barriers to a precisely defined anatomical target. Unlike passive transdermal approaches, our platforms use active mechanisms to direct therapy to where it is needed—reducing required dosage, limiting off-target exposure, and making the delivery event itself clinically purposeful.
Therapeutic presence that persists over clinically meaningful durations, supporting the tissue remodeling and regenerative processes that require time. Moving beyond symptom management, our platforms maintain target-site concentrations capable of driving genuine structural and functional recovery—not just transient symptomatic relief.
The three pillars are interdependent by design. A therapy that is smart but poorly directed wastes efficacy. A therapy that is steered but not sustained forfeits regenerative potential. Vector's platform architecture holds all three properties simultaneously—across device, formulation, and clinical protocol—to deliver interventions that equip clinicians with genuinely differentiated tools.
Our first commercial platform, currently in pre-launch development, brings the Smart, Steered, Sustained framework to clinical practice.
VectorMist™ is Vector Science's first commercial platform—built end-to-end on the Smart, Steered, Sustained framework and designed for clinical environments where precision and safety of delivery are non-negotiable.
Platform details, clinical indications, and commercial terms are not publicly disclosed at this stage. Credentialed inquiries are welcome through our contact channel.
Vector's platform architecture is designed to serve clinical settings where localized, non-systemic intervention offers a meaningful clinical advantage. The following reflects the breadth of applicability—not a full indication listing.
Settings involving joint, tendon, or soft tissue pathology where systemic dosing carries disproportionate risk relative to benefit, and where sustained local therapeutic presence supports the regenerative process.
Clinical contexts characterised by persistent tissue-level pathology, where sustained, site-directed intervention offers a meaningful advantage over systemic or cyclical pharmacological regimens.
High-performance clinical environments demanding rapid, effective intervention with minimal pharmacological side-effect profiles—where return-to-function timelines are clinically and commercially significant.
Settings requiring targeted analgesic or anti-inflammatory support in the post-operative period, where systemic drug loads compound other pharmacological demands and local approaches are clinically preferable.
Everyday clinical settings managing musculoskeletal complaints at volume, where a non-opioid, clinician-administered option enables differentiated patient care within standard-of-care visit structures.
Specialist environments where patients with complex chronic conditions require sophisticated, non-systemic therapeutic options that conventional pharmacological approaches have not adequately resolved.
VectorMist™ is currently in pre-commercial development. Detailed platform specifications, indication scope, and commercial terms are available to qualified clinical partners and institutional investors under appropriate engagement. We welcome substantive conversations with healthcare organizations, clinicians, and capital partners aligned with our mission.